The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.
Site Search
The Cystic Fibrosis Foundation supports universal masking in school to protect people with CF and other health conditions against COVID-19.
The treatment has the potential to prevent Aspergillus fungal infections in people who have had a lung transplant.
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
More than 60 teens from across the country — 25 of whom live with cystic fibrosis — participated online and on Capitol Hill in the Foundation’s Teen Advocacy Day to advocate for the CF community.
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
Foundation welcomes new members to advance its mission